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T-cell receptor polymorphism 
in primary biliary cirrhosis
Carlo Selmi, Pietro Invernizzi, Pasquale Tripputi, Pier Maria Battezzati, Monica Bignotto, 
Massimo Zuin, Andrea Crosignani, Mauro Podda
T-cell receptor (TCR) plays a key role in immune regulation and polymorphisms of its genes have
been found in association with several autoimmune diseases. No data are available for primary
biliary cirrhosis, an autoimmune liver disease the natural history of which is highly variable. We
studied a TCR constant beta-2 chain polymorphism in 70 patients affected by primary biliary cir-
rhosis and in 70 healthy controls. The DNA chains of patients and controls were amplified by means
of polymerase chain reaction using primers designed around a Bgl II polymorphic restriction site
and digested for restriction fragment length polymorphism analysis. We found a slight increase
of the heterozygous genotype in patients compared with controls (49 vs 40%), which became high-
er if only patients with early disease were considered (60 vs 40%). Heterozygous patients had less
severe disease as indicated by a lower Mayo score (5.1 ± 1.2 vs 5.7 ± 1.2 in non-heterozygous). Our
data suggest that TCR constant beta-2 polymorphism does not play a key role in modulating the
multifactorial etiopathogenesis of primary biliary cirrhosis.
(Ann Ital Med Int 2003; 18: 149-153)
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Introduction
Primary biliary cirrhosis (PBC) is a chronic, autoimmune
liver disease with an increased incidence in given fami-
lies and a highly variable course1. An increased incidence
of the disease in the close relatives of patients suggests the
presence of genetic factors in determining the susceptibility
to this pathology2.
Disease association studies have shown a possible role
of the major histocompatibility complex (MHC); the most
consistent association has been found with HLA-DR83,4. 
As in other autoimmune diseases, an abnormal regula-
tion of the immune system is involved and T-cell recep-
tor (TCR), one of the key factors in regulating the immune
response, may be involved5. Interestingly, an abnormal
adaptive immune system has been well documented in
PBC6.
Unlike antibodies that recognize antigens as such, the
TCR recognizes antigens as a complex of short peptides
bound to a MHC molecule on the surface of the antigen
presenting cell. The recognition of the antigen leads to an
extensive array of temporally ordered biological respons-
es involving all the T-cells of a given functional pheno-
type7. TCRs are heterodimers composed of either alpha and
beta or gamma and delta chains; each chain has a variable
region involved in antigen recognition, two chain-specif-
ic regions named joining and diversity and a constant
region which interacts with the CD3 complex on the T-cell
surface8. As the diversity of TCR beta chain is generated
by a random joining of different genes, polymorphisms in
TCR genes are carefully studied in order to determine
whether they play a role in the abnormal immune response
to antigens, possibly leading to a susceptibility to autoim-
mune diseases9.
A polymorphism of the constant region of the beta-2
gene has been investigated in several autoimmune diseases
and has been found to be associated with type I diabetes
mellitus10, autoimmune hepatitis11, immunoglobulin A
nephropathy12 and membranous nephropathy13. In these
studies the polymorphism was investigated by restriction
fragment length polymorphism analysis using Bgl II diges-
tion of the genomic DNA in Southern blot experiments.
At nucleotide sequence analysis of the region, we found
the position of the nucleotide change to be 300 bp before
the beta-2 chain transcription site14. Because this poly-
morphism is in the promoter region of the TCR beta gene,
it could influence gene expression and play a functional
role in autoimmune diseases. We studied for the first time
this polymorphism in 70 PBC patients and 70 controls,
using polymerase chain reaction (PCR) amplification and
restriction enzyme digestion. The allele frequencies in
patients and controls were determined and the clinical
characteristics of the patients as well as their genotypes
were discussed.
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ly described18. PCR was performed with 30 cycles at
93°C for 1 min, 55°C for 1 min and 72°C for 1 min19,
using primers designed around the polymorphic Bgl II
site, according to the sequences of the National Center
for Biotechnology Information web site program (Gene
Bank access number U66061) (forward primer: 5’
TAATTTTGAAATAAGGGAAGATGAC 3’ - reverse
primer: 5’ TTTTGTATCCACCCTATGGGTTGGC 3’).
The DNA was digested at 37°C for 6 hours as previous-
ly described20 and samples were run on ethidium bro-
mide-stained 2% agarose gel. The PCR amplification
product was a 603 bp fragment and restriction with Bgl II
gave rise to two fragments of 203 and 400 bp. As the T/C
polymorphism may lead to the disappearance of the Bgl
II site, the presence of three bands showed heterozygos-
ity of the 603 bp band alone homozygosity for the C
nucleotide and of bands of 203 and 400 bp homozygosi-
ty for the T nucleotide (Fig. 1).
Statistical analysis
To compare the groups of patients the χ2 and the Fisher’s
exact tests were used in the analysis of categorical vari-
ables. With regard to the comparison of the genotype fre-
quencies, significance levels were corrected for multiple
testing using the Bonferroni inequality method. In this pro-
cedure, the p values obtained for each genotype compar-
ison are corrected (pB) by multiplying by the number of
genotypes compared, i.e., by 3. With regard to continuous
variables, the Mann-Whitney test was used to compare two
groups, and the Kruskal-Wallis non-parametric one-way
analysis of variance test to compare more than two groups.
Statistical comparisons were made using the Stata
Statistical Software (Stata Corporation, College Station,
TX, USA). All analyses were two-sided, and p values of
< 0.05 were considered statistically significant.
Methods
Subjects
The PBC population consisted of 70 patients; 10 mL of
whole blood was drawn in order to extract the total DNA
to be tested for the presence of the TCR constant beta-2
genotype. We included in the study 35 patients with his-
tological or clinical evidence of liver cirrhosis and 35
with no evidence of advanced disease, who were admit-
ted to our Division from September 1999 to March 2000.
The diagnosis of PBC was based on internationally accept-
ed criteria1. Eight of the 70 patients were antimitochon-
drial antibody-negative. As they otherwise met the diag-
nostic criteria for the disease we considered them as hav-
ing antimitochondrial antibody-negative PBC, as previ-
ously reported15,16. All patients had to be negative for
hepatitis B surface antigen and for antibodies to hepatitis
C virus. The duration of disease was calculated as the time
between the date of the earliest suspected evidence of
liver disease and the date of blood sampling. The patients
with no fibrosis at liver biopsy, i.e. those in Ludwig’s stages
I and II17, were considered as having early-stage disease;
those with fibrosis or cirrhosis (i.e. stage III or IV) were
considered as having advanced disease. The major char-
acteristics of the patients are shown in table I.
Seventy healthy subjects (62 females and 8 males)
matched by gender and ethnic origin were chosen as con-
trols among students and laboratory staff. The study pro-
tocol followed the ethical guidelines of the 1975 Declaration
of Helsinki and subsequent modifications, and all of the
patients and healthy controls gave their written consent after
being informed about the nature of the study.
T-cell receptor constant beta-2 genotyping
The DNA was extracted by proteinase K digestion,
phenol extraction and ethanol precipitation as previous-
TABLE I. Characteristics of the primary biliary cirrhosis (PBC) patients at the time of blood sampling.
All patients PBC
(n = 70) Early disease Advanced disease p*
(n = 35) (n = 35)
No. females 62 (89%) 31 (89%) 31 (89%) –
Age (years) 59 ± 14 55 ± 13 63 ± 13 0.0157
Total bilirubin (mg/dL; n.v. < 1.0) 0.8 ± 0.4 0.7 ± 0.3 0.9 ± 0.5 –
Albumin (g/dL; n.v. > 3.5) 4.3 ± 0.4 4.4 ± 0.4 4.2 ± 0.5 0.1195
Prothrombin time (INR; n.v. < 1.2) 0.98 ± 0.09 0.97 ± 0.08 0.99 ± 0.10 –
With ascites (n =) 6 (9%) 1 (3%) 5 (14%) 0.1980
With associated diseases** (n =) 20 (29%) 10 (29%) 10 (29%) –
Mayo score value 5.17 ± 0.84 4.77 ± 0.69 5.57 ± 0.79 0.0004
Disease duration (years) 11 ± 6 10 ± 7 13 ± 6 0.0481
Values are expressed as means ± standard deviation.
* early versus advanced disease (values < 0.2 level are shown); ** autoimmune diseases most frequently associated with PBC (autoimmune thyroid dis-
ease, scleroderma, Sjögren’s syndrome).
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Results
Table II shows the TCR constant beta-2 genotypes of the
PBC groups. A slight increase in the frequency of the het-
erozygous status for the T/C residues was found in patients
as compared with controls: 49 vs 40%. If only the 35
patients with early stage PBC were considered, the dif-
ference became higher (60 vs 40% in controls).
The prevalence of the heterozygous status differed
between patients with early and patients with advanced
disease (60 vs 37%, p = 0.093); the difference in clinical
stage of disease among patients became statistically sig-
nificant (p = 0.032) when only patients with the T/C and C/C
genotypes were compared (Table II). Heterozygous patients
(Table III) were significantly younger and had less advanced
disease, as highlighted by earlier histologic stage and lower
values of the Mayo score, a validated prognostic index
developed for PBC21. Serum albumin and prothrombin
levels were also slightly higher in heterozygous patients.
Discussion
PBC is known to be an autoimmune disease with many
factors determining the susceptibility and severity of dis-
ease expression1. As PBC presents a wide spectrum of
severity and of the rate of progression to cirrhosis, with
some patients remaining asymptomatic with histologi-
cally early disease for several decades after the time of
onset22 and others progressing rapidly to advanced disease,
it would be of great interest to determine the genetic
marker(s) of disease progression.
We found an association between the T/C genotype
and less advanced disease as shown by the differing Mayo
score between groups, although the younger age of patients
in the T/C group could have exerted a confounding effect.
Several polymorphic loci have recently been studied in
order to identify genetic factors which, in association
with MHC, may explain the variable susceptibility to
PBC and the different progression rates.
Previous evidence showed that TCRs play a funda-
mental role in the altered immune reaction leading to
autoimmune disease development. Several studies demon-
strated that TCR constant beta-2 polymorphism may be
considered as a factor modulating the progression and
severity of autoimmune diseases. In autoimmune hepati-
tis11, type I diabetes mellitus10, immunoglobulin A
nephropathy12 and membranous nephropathy13 the T/C
genotype has been associated with a later onset and with
less advanced disease.
In our study we performed TCR constant beta-2 geno-
typing of PBC patients and found a non-significant allel-
ic distribution between patients and healthy controls;
FIGURE 1. Agarose gel stained with ethidium bromide showing
in lane 1 the homozygous C pattern (without restriction by Bgl
II), in lane 2 the heterozygous pattern and in lane 3 the homozy-
gous T pattern (complete restriction by Bgl II). The molecular
weights of the polymerase chain reaction products are shown.
TCR genotype Controls All patients PBC
(n = 70) (n = 70) Early disease Advanced disease pB*
(n = 35) (n = 35)
T/T (n =) 21 (30%) 21 (30%) 10 (29%) 11 (31%) –
T/C (n =) 28 (40%) 34 (49%) 21 (60%) 13 (37%) 0.2790
C/C (n =) 21 (30%) 15 (21%) 4 (11%) 11 (31%) 0.2346
TABLE II. Distribution of alleles in primary biliary cirrhosis (PBC) patients and controls.
TCR = T-cell receptor.
* the significance levels are reported after correction (pB) for multiple testing.
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however some differences between early and advanced dis-
ease were found. This finding could be explained by the
role played by other factors (i.e. MHC) in determining the
disease susceptibility; thus the PBC population may be
genetically different from normal controls. The allelic
association with different stages of the disease may be due
to a gene dosage effect caused by the different nucleotide
in the promoter region which, in turn, could explain the
lower prevalence of the homozygous C genotype and the
higher prevalence of the heterozygous T/C genotype in
early stage PBC found in our study. A semiquantitative
PCR analysis to determine the exact amount of the TCR
beta could support this hypothesis. 
Riassunto
Il recettore dei linfociti T (TCR) svolge un ruolo fon-
damentale nella regolazione del sistema immunitario e po-
limorfismi dei suoi geni sono stati descritti in associazione
ad alcune malattie autoimmuni. Non sono disponibili da-
ti relativi a polimorfismi del TCR in pazienti con cirrosi
biliare primitiva, una malattia autoimmune del fegato ca-
ratterizzata da una grande variabilità della sua storia na-
turale. Abbiamo studiato un polimorfismo della catena be-
ta-2 costante del TCR in 70 pazienti affetti da cirrosi bi-
liare primitiva e 70 controlli sani. DNA di pazienti e di con-
trolli è stato amplificato mediante reazione polimerasica
a catena usando primers disegnati intorno al sito poli-
morfico di restrizione Bgl II e digerito per l’analisi del po-
limorfismo della lunghezza dei frammenti di restrizione.
È emerso un modesto aumento del genotipo eterozigote
nei pazienti rispetto ai controlli (49 vs 40%), che diven-
tava più marcato se si consideravano solo i pazienti con
malattia in stadio iniziale (60 vs 40%). I pazienti eterozi-
goti avevano una malattia meno severa come indicato da
un più basso punteggio Mayo (5.1 ± 1.2 vs 5.7 ± 1.2 nei
non eterozigoti). I nostri dati suggeriscono che il poli-
morfismo della catena beta-2 costante del TCR sembra non
svolgere un ruolo importante nel modulare l’eziopatoge-
nesi multifattoriale della cirrosi biliare primitiva.
Parole chiave: Cirrosi biliare primitiva; Reazione poli-
merasica a catena; Recettore dei linfociti T. 
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